This company listing is no longer active
OK10 Stock Overview
A clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
OKYO Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.36 |
| 52 Week High | US$2.84 |
| 52 Week Low | US$1.05 |
| Beta | -2.91 |
| 1 Month Change | 0% |
| 3 Month Change | -4.23% |
| 1 Year Change | -31.66% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -31.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| OK10 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.6% | 0.8% |
| 1Y | -31.7% | -12.3% | 14.6% |
Return vs Industry: OK10 underperformed the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: OK10 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| OK10 volatility | |
|---|---|
| OK10 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: OK10 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine OK10's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 8 | Gary Jacob | okyopharma.com |
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain.
OKYO Pharma Limited Fundamentals Summary
| OK10 fundamental statistics | |
|---|---|
| Market cap | €38.30m |
| Earnings (TTM) | -€15.54m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.5x
P/E RatioIs OK10 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OK10 income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£6.85m |
| Gross Profit | -UK£6.85m |
| Other Expenses | UK£6.42m |
| Earnings | -UK£13.27m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.52 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -107.9% |
How did OK10 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/08/21 03:47 |
| End of Day Share Price | 2023/05/24 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2023/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
OKYO Pharma Limited is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yi Chen | H.C. Wainwright & Co. |
| Ashok Kumar | ThinkEquity LLC |